LYON, France--(BUSINESS WIRE)--Mar 21, 2013--The MEDICREA group (FR0004178572-ALMED), listed on Alternext by NYSE Euronext Paris, a medical company specialized in the development of innovative surgical technologies for the treatment of spinal pathologies, announced today the FDA approval of the PASS® LP system for the treatment of adolescent idiopathic scoliosis. The PASS® LP is the lowest profile pedicle screw spinal fusion system available on the market and has been designed to address the most complex spinal pathologies making it specifically adapted to pediatric indications.
“Medicrea is deeply committed to advancing care for scoliosis patients and we have developed technologies like PASS LP to put new capabilities into the hands of surgeons who treat the most complex spinal deformities,” stated Denys SOURNAC, MEDICREA’s President and CEO. “ We are extremely pleased to announce the approval for this new indication.” The PASS® LP thoraco-lumbar fixation system allows connection of the rod at a distance from the spine and performs a 3D correction of the deformity through gentle and progressive stress distribution on all anchorages using the ST2R technique (Simultaneous Translation on 2 Rods). Through its proprietary derotation connectors & technique, the PASS LP offers a unique way to achieve correction of the deformity in all planes. Derotation in the coronal plane is obtained with no risk of screw ploughing or pull out while preserving sagittal balance, essential in the treatment of adolescent idiopathic scoliosis.
To learn more about MEDICREA and the PASS LP spinal fixation system, please visit MEDICREA website at www.medicrea.com or visit us at POSNA 2013.
MEDICREA specializes in the design, development, manufacture and distribution of orthopedic implants dedicated to spinal surgery. In a $9 billion market, MEDICREA is a very dynamic small to medium-sized business of 100 employees with unique innovation capabilities. The Company enjoys an excellent and ever-improving reputation and develops unique relationships with the most visionary and creative spine surgeons in France, the UK, and the USA. Products developed and patented by MEDICREA provide neurosurgeons and orthopedic surgeons specialized in the spine with new and less-invasive surgical solutions that are faster and easier to implement than traditional techniques. The Group’s headquarters are based in Lyon, France, and it also has a manufacturing facility located in La Rochelle as well as three distribution subsidiaries in the USA, the UK and France.
LYON, France--(BUSINESS WIRE)--Mar 21, 2013--The MEDICREA group, listed on Alternext by NYSE Euronext Paris, a medical company specialized in the development of innovative surgical technologies for the treatment of spinal pathologies, announced today the FDA approval of the...